ClinicalTrials.gg
CompletedNCT04520451Updated Oct 14, 2025

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants

A Phase 2 interventional study of rilzabrutinib and Glucocorticoids in Immunoglobulin G4 Related Disease, sponsored by Principia Biopharma, a Sanofi Company. Completed at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-14.

Sponsored by Principia Biopharma, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2024, 2 years 1 month ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Oct 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Immunoglobulin G4-Related Disease with a site in United States — 4 open to participants now, 7 under way, 3 of them phase 3. Immunoglobulin G4-Related Disease · United States.

Enrollment
5th of 12
27 · median 18
Started
2020
with 1 other
Phase 2
7 of 14
1 open now
Registered
6th of 14
by date
Lead sponsor
1 of 14
Principia Biopharma, a Sanofi Company

Among the 14 studies in Immunoglobulin G4-Related Disease with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 in phase 2, and was the 6th registered.

Immunoglobulin G4-Related Disease

72 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

4 of the 14 studies in Immunoglobulin G4-Related Disease with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Immunoglobulin G4-Related Disease studies recruiting now, 12 (43%) set no upper age limit and 13 (46%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Immunoglobulin G4-Related Disease with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a, multi-center, open-label, two-arm study of approximately 25 patients with active IgG4-related disease (IgG4-RD). The two arms include (1) Experimental: rilzabrutinib with glucocorticoids and (2) Active Comparator: glucocorticoids only.

Read the detailed description

4 weeks of screening, 12 weeks of main treatment, 12 weeks of cross-over (for GC-only group), 40 weeks of extension treatment and 4-week follow-up.

03

Conditions studied

  • Immunoglobulin G4 Related Disease

Keywords

  • +IgG4
  • glucocorticoid
  • IgG4-RD
  • BTK
  • Bruton's
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Be male or female with age ≥18 years.
  • Have a clinical diagnosis of IgG4-RD.
  • Be willing to taper off an equivalent prednisone dose of between 20-40 mg/day in 2 weeks.

Key Exclusion Criteria:

  • Currently or within 6 months of screening taking rituximab, other B-cell depleting agents, or alkylating agents unless B cell concentrations have been demonstrated by flow cytometry to return to normal values (defined as 5 cells per cubic mm).
  • History of solid organ transplant
  • Positive at Screening for , , , or TB
  • Female patients who are pregnant or nursing.
  • NOTE: Other Inclusion/Exclusion criteria may apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Rilzabrutinib + glucocorticoids

    Rilzabrutinib tablets, 400 mg twice daily from Week 0 to Week 12 plus glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 2 weeks on study)

    Drug: rilzabrutinib · Drug: Glucocorticoids

  • Active comparator
    Glucocorticoids

    Glucocorticoids (20 to 40 mg/day prednisone equivalent tapered to 0 mg/day within 12 weeks on study)

    Drug: Glucocorticoids

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants who are without disease flare following the first dose of rilzabrutinib until the end of treatment

    Disease flare is defined as an increase in IgG4-RD responder index (RI) \>2 or initiation of rescue treatment.

    Time frame: Up to 64 weeks

  2. Incidence of SAE, AE leading to discontinuation and possible glucocorticoid-related AE

    Time frame: Up to 68 weeks

  3. Number of participants with Potentially clinically significant abnormalities (PCSAs) for clinical laboratory tests, vital signs and ECG

    Time frame: Up to 68 weeks

Secondary outcomes

  1. Proportion of participants with reduction from baseline IgG4-RD RI activity score by ≥2 points over time

    Time frame: At Week 52

  2. Proportion of patients with an IgG4-RD RI activity score = 0 at over time

    Time frame: Up to 64 weeks

  3. Level and change from baseline of each subclass of the serological markers over time

    serum protein electrophoresis to determine IgG subclasses and complement factors C3 and C4

    Time frame: Up to 64 weeks

  4. Proportion of participants achieving reduction in baseline serum IgG4 level of 10% over time

    Time frame: Up to 64 weeks

  5. Change from baseline in IgG4-RD RI over time

    Time frame: From baseline up to 64 weeks

  6. Change from baseline in IgG4-RD damage, as recorded on the damage portion of the IgG4-RD RI over time

    Time frame: From baseline up to 64 weeks

07

Study locations

9 sites
  • Investigational Site Number 84019
    Stanford, California 94305, United States
  • Investigational Site Number 84016
    Boston, Massachusetts 02114, United States
  • Investigational Site Number 84018
    Detroit, Michigan 48202, United States
  • Investigational Site Number 84030
    New York, New York 10021, United States
  • Investigational Site Number 84036
    Portland, Oregon 97239, United States
  • Investigational Site Number 12403
    Vancouver, V6K 2V8, Canada
  • Investigational Site Number 25013
    Marseille, France
  • Investigational Site Number 38016
    Milan, Italy
  • Investigational Site Number 72415
    Barcelona, Spain
08

References and documents

Publications

  • Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH; ACR/EULAR IgG4-RD Classification Criteria Committee. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. Ann Rheum Dis. 2019 Mar;78(3):406-412. doi: 10.1136/annrheumdis-2018-214603. Epub 2019 Jan 5. PubMed 30612117 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Oct 2024, 49 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2020
First posted
Aug 20, 2020
StartActual
Aug 22, 2020
Primary completionActual
Oct 15, 2024
CompletionActual
Oct 15, 2024
Results delay requested
Oct 10, 2025
Last update
Oct 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04520451
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Aug 22, 2020
Primary completion
Oct 15, 2024
Completion
Oct 15, 2024
Last update
Oct 14, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rilzabrutinib

Start the discussion